Provided by Tiger Trade Technology Pte. Ltd.

Fortress Biotech

3.61
+0.12003.44%
Post-market: 3.640.0300+0.83%18:11 EST
Volume:270.68K
Turnover:977.02K
Market Cap:112.05M
PE:-12.32
High:3.70
Open:3.49
Low:3.45
Close:3.49
52wk High:4.53
52wk Low:1.33
Shares:31.04M
Float Shares:23.51M
Volume Ratio:0.43
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2930
EPS(LYR):-2.6890
ROE:-205.29%
ROA:-34.25%
PB:2.01
PE(LYR):-1.34

Loading ...

Fortress Biotech Gains FDA Approval for Menkes Treatment

TIPRANKS
·
Jan 13

Fortress Biotech Shares Hit Near Two-Week Low, Last Down 6.6%

THOMSON REUTERS
·
Jan 13

FDA Approves Fortress Biotech’s ZYCUBO for Menkes Disease

Reuters
·
Jan 13

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of Zycubo® (Copper Histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

THOMSON REUTERS
·
Jan 13

Fortress Biotech Inc - Cyprium Eligible for up to $129 Mln in Milestones

THOMSON REUTERS
·
Jan 13

Fortress Biotech Inc - Rare Pediatric Disease Voucher to Be Transferred to Cyprium

THOMSON REUTERS
·
Jan 13

Fortress Biotech Climbs on Revised Credit Agreement

Dow Jones
·
Jan 13

Avenue Therapeutics Inc. Held Annual Shareholder Meeting

Reuters
·
Dec 31, 2025

Mustang Bio Director David Jin Reports Acquisition of Common Shares

Reuters
·
Dec 31, 2025

Mustang Bio Inc. held annual shareholder meeting

Reuters
·
Dec 24, 2025

Fortress Biotech Announces Unregistered Sale of Warrants in Private Placement

Reuters
·
Dec 16, 2025

FDA Accepts Fortress Biotech and Cyprium Therapeutics CUTX-101 NDA Resubmission

Reuters
·
Dec 15, 2025

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of Cutx-101 Nda Resubmission

THOMSON REUTERS
·
Dec 15, 2025

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (Dfd-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

THOMSON REUTERS
·
Dec 10, 2025

Avenue Therapeutics Inc. Announces Date for Upcoming Annual Stockholder Meeting

Reuters
·
Dec 06, 2025

Mustang Bio Inc. Announces Date for Upcoming Annual Stockholder Meeting

Reuters
·
Dec 04, 2025

Fortress Biotech Jumps in Volume Spike, Last up 3.7%

THOMSON REUTERS
·
Dec 04, 2025

BRIEF-Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA

Reuters
·
Nov 17, 2025

Sentynl Resubmits CUTX-101 NDA to FDA for Menkes Disease Treatment

Reuters
·
Nov 17, 2025

Fortress Biotech Inc: on Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted the Nda for Cutx-101 to the FDA

THOMSON REUTERS
·
Nov 17, 2025